Unsafe
Not Aligned
Patient Risk:
High
Summary
Most extracted claims are marked as not supported by the provided FDA-approved label content (e.g., discount card operations/eligibility). Only the drug-interaction-related statements about sedation/respiratory depression with CNS depressants/alcohol are supported by the label excerpts provided. Overall, the response content is largely label-inconsistent for the requested label alignment basis.
Category Scores
Accurate Statements
Patients commonly ask about sedation and breathing suppression risk when using oxycodone HCl, especially if they also take other sedatives.
Supported in substance by label warnings that concomitant use of XTAMPZA ER with benzodiazepines/other CNS depressants (including alcohol) may result in profound sedation and respiratory depression, among other severe outcomes (Warnings and Precautions 5.3; Drug Interactions section 7).
Oxycodone HCl may interact with other medications (including alcohol and sedatives).
Supported by label Drug Interactions (7): Benzodiazepines and other CNS depressants, including alcohol, increase risk of respiratory depression, profound sedation, coma, and death; and Warnings and Precautions (5.3) with similar language.
Unsupported Statements
Most discount cards are designed to reduce the cash price for generic medications when they’re available.
No support in the provided XTAMPZA ER label excerpts (label content provided concerns opioid prescribing/safety, not discount-card mechanics).
Discount cards require the exact medication name and formulation (for example, oxycodone hydrochloride / oxycodone HCl).
Not supported by the provided label excerpts.
Discount cards require the exact strength (for example, 5 mg, 10 mg, 15 mg, etc.).
Not supported by the provided label excerpts.
Discount cards require the correct release type (immediate-release vs. extended-release).
Not supported by the provided label excerpts.
If a substitute or different formulation is received, the discount may not apply.
Not supported by the provided label excerpts.
Pharmacies generally need medication name, strength, dosage form (immediate-release or extended-release), and quantity to verify the card’s eligible drug match before applying the discounted rate.
Not supported by the provided label excerpts.
Discount cards usually apply to cash-paying patients.
Not supported by the provided label excerpts.
Discount cards may not stack with insurance copays.
Not supported by the provided label excerpts.
If you have coverage, the pharmacy typically bills insurance first and then you may pay a copay unless the program explicitly allows stacking.
Not supported by the provided label excerpts.
Many discount programs do not allow stacking with insurance.
Not supported by the provided label excerpts.
Oxycodone HCl is generally widely available as a generic medication.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Label-based contraindications and key warnings beyond the CNS depressant/alcohol interaction (e.g., boxed/serious respiratory depression timing, contraindications such as significant respiratory depression, acute/severe bronchial asthma, GI obstruction/paralytic ileus, hypersensitivity to oxycodone) were not addressed in the provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The majority of claims are unrelated to the FDA label content provided (discount card operations). While not directly pharmacologically incorrect, this represents a high-risk alignment failure because the response does not primarily reflect FDA-approved prescribing-information facts and may mislead readers relying on label-accurate guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are absent from the provided FDA-approved label excerpts; only CNS depressant/alcohol interaction-related safety content is supported.
Suggested Improvement
Restrict factual claims to information explicitly present in the FDA-approved prescribing information provided (e.g., opioid respiratory depression risk and contraindications/warnings; specific drug-interaction warnings). Remove or clearly separate non-label business/discount-card mechanics claims, which are not supported by the label.